RxDoctor Payments Data

Sumayya Ahmad, MD

Ophthalmology · Long Island City, NYNPI 1760777064

Payments from drug & device makers

$101,401in general payments, 2019–2025

Across 57 payments — averaging $1778.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$72K
  • Recordati_rare_diseases_inc.$19K
  • Regeneron$6K
  • Arcutis Biotherapeutics, Inc.$3K
  • Dompe US, Inc.$298
  • Glaukos Corporation$204
  • plus $849 from 8 others

What the payments were for

  • Consulting fees$2,62563%
  • Food & beverage$1,43034%
  • Education$1002%
  • Gifts$301%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,401 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$191,812
Medicare patients
483
Services billed
1,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast81$66,803
RestasisCyclosporine44$26,858
Prednisolone Acetate465$15,350
TyrvayaVarenicline Tartrate11$7,238
LumiganBimatoprost14$6,584
RocklatanNetarsudil Mesylat/Latanoprost16$5,369
Loteprednol Etabonate13$3,279
Ketorolac Tromethamine181$3,012
Latanoprost173$1,239
Ciprofloxacin Hcl110$1,159
Brimonidine Tartrate55$1,055
ValacyclovirValacyclovir Hcl41$732
Fluorometholone13$666
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat56$594
MoxifloxacinMoxifloxacin Hcl30$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$71,992$7,23811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Long Island City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →